German observational study of the tolerability of enteric-coated acetylsalicylic acid and its presentation in Russian publications 2009-2018

Bel'diev S. N.
PhD, Associate Professor, Chair for Therapy and Cardiology¹

Berezina E. I.
PhD, Associate Professor, Chair for Therapy and Cardiology¹

Gavrilenko N. G.
PhD, Associate Professor, Chair for Foreign Languages and Latin¹

Egorova I. V.
PhD, Assistant, Chair for Therapy and Cardiology¹

Medvedeva I. V.
PhD, Associate Professor, Chair for Therapy and Cardiology¹

Platonov D. Ju.
Doctor of Medicine, Head, Chair for Therapy and Cardiology¹

1 - Tver State Medical University, Tver, Russia

Bel'diev Sergej; e-mail: sbeldiev@yandex.ru

None declared.

The study had no sponsorship.

The article discusses the inaccuracies made in some Russian publications when quoting a German-language paper presenting the results of a two-year observational study of the tolerability of enteric-coated acetylsalicylic acid.

acetylsalicylic acid, enteric-coated form, tolerability, observational study, validity, translation equivalence

10.29234/2308-9113-2019-7-1-26-41

1. Arkhipov M.V. Vybor antitrombocitarnoj terapii u pacientov so stabil'noj stenokardiej [Selection of antiplatelet therapy for patients with stable angina]. Kardiologia [Cardiology] 2018; 58(S1): 36-41. doi: 10.18087/cardio.2402. (In Russ.)

2. Perepech N.B., Mikhailova I.E. Antiagreganty v pervichnoj profilaktike serdechno-sosudistyh zabolevanij i profilaktike aterotromboza u bol'nyh so stabil'noj formoj ishemicheskoj bolezni serdca: aspekty jeffektivnosti i bezopasnosti [Antiaggregants in primary prevention of cardiovascular diseases and in prevention of atherothrombosis in patients with stable ischemic heart disease: aspects of efficacy and safety]. Kardiologiia [Cardiology] 2018; 58(2): 55-67. doi: 10.18087/cardio.2018.2.10035. (In Russ.)

3. Tarlovskaya E.I. Formy vypuska i dozy acetilsalicilovoj kisloty: znachenie dlja klinicheskoj praktiki [Dosage forms and doses of acetylsalicylic acid: significance for clinical practice]. Kardiologiia [Cardiology] 2018; 58(S5): 4-12. doi: 10.18087/cardio.2466. (In Russ.)

4. Dammann H.G., Burkhardt F., Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 1999; 13(8): 1109-14. doi: 10.1046/j.1365-2036.1999.00588.x.

5. Dietz R., Rauch B. Guidelines for diagnosis and treatment of chronic coronary heart disease. Issued by the executive committee of the German Society of Cardiology – Heart Circulation Research. Z Kardiol 2003; 92(6): 501-21. doi: 10.1007/s00392-003-0960-1. (In Germ.)

6. Kübler W., Darius H. Primary prevention of coronary heart disease with aspirin. Z Kardiol 2005; 94(Suppl 3): III/66-73. doi: 10.1007/s00392-005-1309-8. (In Germ.)

7. Rafalsky V.V., Krikova A.V., Baglikov A.N. Osobennosti klinicheskoj farmakologii acetilsalicilovoj kisloty kak antitromboticheskogo preparata [Clinical pharmacology of acetylsalicylic acid as an antithrombotic agent]. Kardiovaskuljarnaja terapija i profilaktika [Cardiovascular Therapy and Prevention] 2009; 8(7): 102-7. (In Russ.)

8. Nebieridze D.V., Meliya A. Pacienty vysokogo riska: sovremennaja strategija lechenija. Kardiovaskuljarnaja terapija i profilaktika [High-risk patients: modern treatment strategy]. Kardiovaskuljarnaja terapija i profilaktika [Cardiovascular Therapy and Prevention] 2010; 9(6): 97-101. (In Russ.)

9. Dlitel'noe primenenie acetilsalicilovoj kisloty. Podhody k povysheniju priverzhennosti terapii [Long-term use of acetylsalicylic acid. Approaches to increasing adherence to therapy]. Consilium Medicum 2017; 19(10): 144-5. (In Russ.)

10. Darius H. Documentation of good tolerability of Aspirin protect in an observational study. Pharm Zeit 2006; 151(34): 3090-98. (In Germ.)

11. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949-3003. doi: 10.1093/eurheartj/eht296.

12. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A. et al. Rekomendacii po lecheniju stabil'noj ishemicheskoj bolezni serdca. ESC 2013 [2013 ESC guidelines on the management of stable coronary artery disease]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology] 2014; 7: 7-79. doi: 10.15829/1560-4071-2014-7-7-79. (In Russ.)

13. DGK. ESC Pocket Guidelines: Management der stabilen koronaren Herzkrankheit (KHK) (Version 2013). Available at: https://leitlinien.dgk.org/2015/pocket-leitlinie-management-der-stabilen-koronaren-herzkrankheit-khk/. Cited 08.02.2019 (In Germ.)

14. de Mey C. Sense and nonsense in post-authorization surveillance. Med Klin (Munich) 2000; 95(1): 56-62. doi: 10.1007/BF03044984. (In Germ.)

15. Dietrich E.S. Most post-marketing surveillance studies in Germany are not useful to generate valid scientific evidence. PharmacoEconomics – German Research Articles 2009; 7(1): 3-14. doi: 10.1007/BF03320755. (In Germ.)

16. Danishevskiy K.D. Vidy issledovanij v dokazatel'noj medicine [Types of studies in evidence-based medicine]. Medicina [Medicine] 2015; (1): 18-30. (In Russ.)

17. Arutyunov G.P., Arhipov M.V., Bakalov S.A., Bokarev I.N., Vyshlov E.V., Gilyarevskiy S.R. et al. Mesto i znachenie nabljudatel'nyh issledovanij NOAK u pacientov s neklapannoj fibrilljaciej predserdij s pozicii mediciny, osnovannoj na dokazatel'stvah [Place and significance of observational studies of NOACs in patients with non-valvular atrial fibrillation from the standpoint of evidence-based medicine]. Serdce: zhurnal dlja praktikujushhih vrachej [Russian Heart Journal] 2016; 15(6): 441-7. doi: 10.18087/rhj.2016.6.2297. (In Russ.)

18. Martsevich S.Yu., Kutishenko N.P. Randomizirovannye klinicheskie issledovanija i nabljudatel'nye issledovanija: sootnoshenie v ierarhii dokazatel'stv jeffektivnosti lekarstv [Randomised clinical trials and observational studies: the ratio in the hierarchy of evidence of the efficacy of drugs]. Racional'naja farmakoterapija v kardiologii [Rational Pharmacotherapy in Cardiology] 2016; 12(5): 567-573. doi: 10.20996/1819-6446-2016-12-5-567-573. (In Russ.)

19. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60. doi: 10.1016/S0140-6736(09)60503-1.

20. Gaziano J.M., Brotons C., Coppolecchia R., Cricelli C., Darius H., Gorelick P.B. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392(10152): 1036-46. doi: 10.1016/S0140-6736(18)31924-X.

21. McNeil J.J., Wolfe R., Woods R.L., Tonkin A.M., Donnan G.A., Nelson M.R. et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018; 379(16): 1509-18. doi: 10.1056/NEJMoa1805819.

22. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 379(16): 1529-39. doi: 10.1056/NEJMoa1804988.

23. Walker J., Robinson J., Stewart J., Jacob S. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Interact Cardiovasc Thorac Surg. 2007; 6(4): 519-22. doi: 10.1510/icvts.2007.155788.

24. Fletcher R.H., Fletcher S.W., Wagner E.H. Klinicheskaja jepidemiologija. Osnovy dokazatel'noj mediciny [Clinical epidemiology. The essentials]. Moscow: Media Sfera, 1998. 352 p. (In Russ.)

25. Averkov O.V. Acetilsalicilovaja kislota kak antitrombocitarnoe sredstvo: kakie lekarstvennye formy preparata predpochtitel'ny s pozicij dokazatel'noj mediciny? [Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine?] Kardiovaskuljarnaja terapija i profilaktika [Cardiovascular Therapy and Prevention] 2010; 9(2): 61-8. (In Russ.)

26. Bubnova M.G. Aspirin v profilaktike aterotromboza i koronarnoj bolezni serdca [Aspirin in the prevention of atherothrombosis and coronary heart disease]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology] 2010; (4): 115-21. doi: 10.15829/1560-4071-2010-4-115-121. (In Russ.)

27. Mychka V.B. Osobennosti antiagregantnoj terapii u zhenshhin [Features of antiplatelet therapy in women]. Jeffektivnaja farmakoterapija [Effective Pharmacotherapy] 2011; 16: 6-10. (In Russ.)

28. Martsevich S.Yu., Tolpygina S.N., Lukina Yu.V. Voronina V.P., Kiseleva N.V., Boychenko E.S. et al. Sravnitel'naja ocenka antiagregantnoj jeffektivnosti original'nogo i vosproizvedennogo preparatov kishechnorastvorimoj formy acetilsalicilovoj kisloty (rezul'taty klinicheskogo issledovanija IKAR) [Comparative evaluation of antiplatelet effectiveness drugs of original and reproduced enteric forms of acetylsalicylic acid (clinical study ICAR)]. Kardiologija [Cardiology] 2012; 1: 74-82. (In Russ.)

29. Strizhakov L.A. Profilaktika serdechno-sosudistyh oslozhnenij pri saharnom diabete: znachenie aspirina [Prevention of cardiovascular complications in diabetes mellitus: the role of aspirin]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology] 2012; 2: 94-9. doi: 10.15829/1560-4071-2012-2-94-99. (In Russ.)

30. Seliverstova D.V., Evsina O.V. Acetilsalicilovaja kislota v pervichnoj profilaktike serdechno-sosudistyh zabolevanij [Acetylsalicylic acid in primary prevention of cardiovascular diseases]. Serdce: zhurnal dlja praktikujushhih vrachej [Russian Heart Journal] 2014; 79(5): 298-302. doi: 10.18087/rhj.2014.5.1987. (In Russ.)